This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
==== Interpretation of results ==== HOMA-IR < 2: normal insulin sensitivity HOMA-IR > 2: possible insulin resistance HOMA-IR > 2,5: probable insulin resistance HOMA-IR > 5: typical results for type 2 diabetes SPINA-GR 1,41–9,00 mol/s: normal insulin sensitivity SPINA-GR ≤ 1,40 mol/s: insulin resistance SPINA-GR < 1,35 mol/s: typical results for type 2 diabetes
=== Function in plants === Plants require magnesium to synthesize chlorophyll, essential for photosynthesis. Magnesium in the center of the porphyrin ring in chlorophyll functions in a manner similar to the iron in the center of the porphyrin ring in heme. Magnesium deficiency in plants causes late-season yellowing between leaf veins, especially in older leaves, and can be corrected by either applying epsom salts (which is rapidly leached), or crushed dolomitic limestone, to the soil.
== Open access type == According to its website, SCIRP publishes fee-based open-access journals (Gold OA). Payments are incurred per article published. Authors are permitted to archive their work (Green OA). Preprint, postprint, and the publisher's PDF version may be used. According to the society's website, journals published are fully open access, with reuse rights based on CC BY or CC BY-NC.
As with the farming of terrestrial animals, social attitudes influence the need for humane practices and regulations in farmed marine animals. Under the guidelines advised by the Farm Animal Welfare Council good animal welfare means both fitness and a sense of well-being in the animal's physical and mental state. This can be defined by the Five Freedoms:
== History == Perhaps the earliest known occurrence of cement is from twelve million years ago. A deposit of cement was formed after an occurrence of oil shale located adjacent to a bed of limestone burned by natural causes. These ancient deposits were investigated in the 1960s and 1970s.
Sources: en.wikipedia.org
The Five Guys menu focuses on hamburgers offered with Kraft American cheese or applewood-smoked bacon and kosher style hot dogs (Hebrew National all-beef franks), as well as grilled cheese, BLT and vegetable sandwiches. Five Guys uses buns that are sweeter and "eggier" than normal buns. The hamburgers come in two sizes: regular (two patties) and little (one patty). Customers may select from 15 toppings at no charge. Fresh-cut french fries are the sole side item, available salted only in "Five Guys style" or seasoned "Cajun style". Conventionally, Five Guys employees are directed to give customers an extra scoop of fries for free when they order. The rationale was to persuade the customer that they were getting a good deal by giving them more fries than they'd paid for. However, the extras were already accounted for in the initial pricing. Complimentary roasted in-shell peanuts are offered for on-site consumption at most locations, with signage alerting potential customers who may have a peanut allergy; for these allergen reasons, customers are not allowed to take peanuts off-site.
Smith developed a way to color code the basic nucleotide units of DNA with fluorescent tags, green for adenine (A), yellow-green for guanine (G), orange for cytosine (C) and red for thymine (T). Four differently colored fluorophores, each one specific to a reaction with one of the bases, are covalently attached to the oligonucleotide primer for the enzymatic DNA sequence analysis. During the analysis, fragments are passed downwards through a gel tube, the smallest and lightest fragments passing through the gel tube first. A laser light passed through a filter wheel causes the bases to fluoresce. The resulting fluorescent colors are detected by a photomultiplier and recorded by a computer. The first DNA fragment to be sequenced was a common cloning vector, M13. The DNA sequencer was a critical technology for the Human Genome Project. Hood was involved with the Human Genome Project from its first meeting, held at the University of California, Santa Cruz, in 1985. Hood became an enthusiastic advocate for The Human Genome Project and its potential. Hood directed the Human Genome Center's sequencing of portions of human chromosomes 14 and 15. At the University of Washington in the 1990s, Hood, Alan Blanchard, and others developed ink-jet DNA synthesis technology for creating DNA microarrays. By 2004, their ink-jet DNA synthesizer supported high-throughput identification and quantification of nucleic acids through the creation of one of the first DNA array chips, with expression levels numbering tens of thousands of genes.
=== Finance === According to Nicolas Firzli, director of the World Pensions & Investments Forum, it may be too early to see the emergence of highly innovative AI-informed financial products and services. He argues that "the deployment of AI tools will simply further automatise things: destroying tens of thousands of jobs in banking, financial planning, and pension advice in the process, but I'm not sure it will unleash a new wave of [e.g., sophisticated] pension innovation."
Aang, in the animated series Avatar: The Last Airbender and The Legend of Korra was vegetarian. According to the show's creators, "Buddhism and Taoism have been huge inspirations behind the idea for Avatar." As shown in "The King of Omashu" and "The Headband", a notable aspect of Aang's character is his vegetarian diet, which is consistent with Buddhism, Hinduism, and Taoism. In the Brahmajala Sutra, a Buddhist code of ethics, vegetarianism is encouraged. Other fictional characters who are vegetarians include Count Duckula in Count Duckula, Beast Boy in Teen Titans and Teen Titans Go!, Lenore in Supernatural, and Norville "Shaggy" Rogers in the animated series What's New, Scooby Doo?. Before the latter animated series, Shaggy was known for having an "enormous appetite" earlier in the Scooby-Doo franchise. The decision to make Shaggy a vegetarian occurred after his voice actor, Casey Kasem, convinced the producers to do so, since he was a vegan who supported animal rights and opposed factory farming, saying he would refuse to voice Shaggy unless the character was vegetarian. An October 2019 South Park episode, "Let Them Eat Goo", featured a vegetarian character. Additionally, Steven Universe, the protagonist in the show Steven Universe and the limited epilogue series, Steven Universe Future, is a vegetarian. In the episode "Snow Day" of Steven Universe Future, Steven tells the Gems he lives with that he has been a vegetarian for a month, drinks protein shakes and mentions that he does "his own skincare routine."
Sources: en.wikipedia.org
Occasionally, Journal Citation Reports assigns an impact factor to new journals with less than two years of indexing, based on partial citation data. The calculation always uses two complete and known years of item counts, but for new titles one of the known counts is zero. Annuals and other irregular publications sometimes publish no items in a particular year, affecting the count. The impact factor relates to a specific time period; it is possible to calculate it for any desired period. For example, the JCR also includes a five-year impact factor, which is calculated by dividing the number of citations to the journal in a given year by the number of articles published in that journal in the previous five years.
== January 20, 1982 (Wednesday) == Musician Ozzy Osbourne was treated for rabies after allegedly biting the head off a live bat during a concert at Veterans Auditorium in Des Moines, Iowa. A spokesman for Broadlawn Medical Center reported that the patient registered as John M. Osbourne "was given a rabies shot and rabies vaccine and a tetanus shot as well," and that the medical report gave the history "Patient bit head off bat." Des Moines police lieutenant Derald Leaming said "I told his manager if he bit the head off any animals while he was here, he'd be arrested. We would have arrested him on the spot if we'd seen anything like that," while two other officers said that he had seen Osbourne "put a couple of birds in his mouth but he let them loose", and that although the police didn't see a bat, that they "did see raw liver on the floor." Born: Pete Buttigieg, American politician, U.S. Secretary of Transportation from 2021 to 2025, 2020 candidate for the Democratic Party nomination for U.S. president; in South Bend, Indiana Died: Marc Demeyer, 31, Belgian professional bicyclist known for winning individual stages twice in the Tour de France (1978 and 1979) and twice in the 1977 Giro d'Italia, died of a heart attack.
==== Genetic engineering ==== The WHO currently bans genetic engineering of the variola virus. However, in 2004, a committee advisory to the WHO voted in favor of allowing editing of the genome of the two remaining samples of variola major virus to add a marker gene. This gene, called GFP, or green fluorescent protein, would cause live samples of the virus to glow green under fluorescent light. The insertion of this gene, which would not influence the virulence of the virus, would be the only allowed modification of the genome. The committee stated the proposed modification would aid in research of treatments by making it easier to assess whether a potential treatment was effective in killing viral samples. The recommendation could only take effect if approved by the WHA. When the WHA discussed the proposal in 2005, it refrained from taking a formal vote on the proposal, stating that it would review individual research proposals one at a time. Addition of the GFP gene to the Vaccinia genome is routinely performed during research on the closely related vaccinia virus.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.